Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30029312 | 1.00 | HTR7 (0.47) | HTR7MAPTCDK9DYRK1ADYRK2 | |
| SCHEMBL30027652 | 0.83 | HTR7 (0.44) | HTR7MAPTCDK9DYRK1ADYRK2 | |
| SCHEMBL24959192 | 0.83 | HTR7 (0.44) | HTR7MAPTCDK9DYRK1ADYRK2 | |
| SCHEMBL30027964 | 0.82 | HTR7 (0.43) | HTR7MAPTRAB9APOLBLMNA | |
| SCHEMBL24959005 | 0.82 | HTR7 (0.43) | HTR7MAPTRAB9APOLBLMNA | |
| SCHEMBL24958756 | 0.82 | HTR7 (0.43) | HTR7MAPTCDK9DYRK1ADYRK2 | |
| SCHEMBL31438106 | 0.82 | HTR7 (0.43) | HTR7MAPTCDK9DYRK1ADYRK2 | |
| SCHEMBL24959231 | 0.79 | HTR7 (0.40) | HTR7MAPTRAB9APOLBLMNA | |
| SCHEMBL24960044 | 0.79 | HTR7 (0.40) | HTR7MAPTRAB9APOLBLMNA | |
| SCHEMBL30029492 | 0.79 | HTR7 (0.40) | HTR7MAPTRAB9APOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117295729-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | HTR7 280/4885MAPT 3314/4885CDK9 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.